AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 211 min read$MED

Kiai Parsa purchased $843K of MED (indirect holdings)

Kiai Parsa purchased 72,487 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.63 ($11.60–$11.66, $0.84M total) across 4 trades over 2026-08-19 to 2026-08-20.

Original reporting
SEC EDGAR · Kiai Parsa
Published Aug 21, 2026, 4:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 21, 2026, 4:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MED
Neutral
medium confidence
Mentioned
$MED
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDNeutralLow
01

Why it matters

The purchase adds modest confidence but unlikely to move the stock significantly.

02

Market read

Small insider buy; limited immediate trading relevance.

03

What to watch

Potential upcoming product launch or earnings could be the real driver.

Relevance 6/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions; MED is a US-listed consumer health company.

Company-level read

Ticker impact

$MEDNeutralMedium confidence
Context

Director Kiai Parsa bought 72,487 shares of Medifast for $842,699, increasing his stake to 18,977 shares.

Expected impact

Potential slight upside pressure; limited impact.

Evidence & confidence

Purchase amount under $1M and indirect ownership suggest modest market reaction.

Market effects

Sector

Minimal effect on consumer health sector.

Regional

No regional impact.

Global

Limited to Medifast investors.

Counterpoint

What could challenge this read

Insider purchase may be routine portfolio rebalancing, not a strong buy signal.

Key entities

  • Director
    Kiai Parsa

    Director of Medifast who purchased shares.

  • Company
    Medifast Inc

    US-listed consumer health company (ticker MED).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MED insider trading history →

Related articles

OCT 28
$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

financialcontent.com2 min
OCT 27
$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

financialcontent.com2 min
OCT 27
$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

finance.yahoo.com2 min
OCT 26
$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

finance.yahoo.com2 min
OCT 26
$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.

finance.yahoo.com2 min